283P - Satisfaction with cancer treatments in HR + /HER2- metastatic breast cancer patients in a real world setting

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Breast Cancer
Presenter Jonathan de Courcy
Citation Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365
Authors J. de Courcy1, R. Wood1, D. Mitra2, S. Iyer2
  • 1Adelphi Real World, Adelphi Group Ltd., SK10 5JB - Bollington/GB
  • 2Global Outcomes And Evidence, Pfizer Inc., 10017 - New York/US

Abstract

Background

To assess patient reported cancer treatment satisfaction in HR + /HER2- metastatic breast cancer (MBC).

Methods

Physicians were recruited into the Disease Specific Program (DSP) across 5 EU countries (UK, FR, DE, ES, IT) and the US. Patients (N = 739) completed self-reported questionnaires which included the Cancer Therapy Satisfaction Questionnaire (CTSQ); this assesses 3 domains, Expectations of Therapy (ET), Feelings about Side Effects (FSE) and Satisfaction with Therapy (SWT). Each domain is scored from 0-100 with a higher score associated with the best outcome. Results are reported for the overall cohort, by current therapy and by metastatic sites. Significance was assessed using Mann-Whitney U and Kruskal-Wallis tests.

Results

A total of 611 MBC patients completed the questionnaire; mean age (SD) 66.3 (10.3). Most patients received either chemotherapy w/o endocrine therapy (46.2%) or endocrine therapy w/o chemotherapy (48.8%). 5.1% received both or neither. Mean scores (SD) for ET, FSE and SWT were 60.6 (21.0), 54.9 (17.5) and 69.4 (15.4) respectively. Domain scores are stratified by current therapy and metastatic sites in Table 1. ET scores did not vary by either stratification. Significantly worse scores were reported in the chemotherapy group for the FSE and SWT domains, while bone and visceral metastases patients reported worse FSE outcomes. When stratified by therapy, patients with bone and visceral metastases scored lower on most domains compared to other metastases groups (not significant).

CURRENT THERAPY METASTATIC SITES (± lymph nodes)
Endocrine (n = 298) Chemotherapy (n = 282) Bone not visceral (n = 195) Visceral not bone (n = 242) Bone & visceral (n = 110)
ET 61.2 (21.1) 61.4 (18.8) 62.6 (20.0) 59.2 (21.9) 57.2 (19.8)
FSE 59.7 (18.4) 50.9 (14.8)* 57.7 (17.3) 53.2 (17.2) 49.5 (15.9)*
SWT 71.6 (15.6) 68.2 (14.0)* 70.9 (14.0) 68.7 (15.7) 65.7 (16.2)

* P 

Conclusions

Therapy expectations do not differ by therapy type or metastatic sites. Patients on chemotherapy appear less satisfied with their treatment and feel worse about their side effects than patients on endocrine therapy. Presence of bone and visceral metastases is associated with worse feelings about side effects.

Clinical trial identification

Legal entity responsible for the study

Adelphi Real World

Funding

Pfizer

Disclosure

J. de Courcy, R. Wood: Adelphi Real World produces research which is funded by pharmaceutical companies. D. Mitra, S. Iyer: Employee of Pfizer, Inc. and owns Pfizer stock